• 1
    Afquir S, Ismaili N, Alaoui K, et al. Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur Arch Otorhinolaryngol. 2009; 266: 1767-1773.
  • 2
    Brennan B. Nasopharyngeal carcinoma [serial online]. Orphanet J Rare Dis. 2006; 1: 23.
  • 3
    Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4: 13-21.
  • 4
    Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976; 17: 1-7.
  • 5
    Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma. Cancer. 2003; 98: 74-80.
  • 6
    Song CH, Wu HG, Heo DS, Kim KH, Park CI. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008; 118: 663-670.
  • 7
    Su SF, Han F, Zhao C, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone [published online ahead of print October 28, 2010]. Int J Radiat Oncol Biol Phys. 2010.
  • 8
    Baujat B, Audry H, Chan AT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of 8 randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006; 64: 47-56.
  • 9
    Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010; 12: 471-477.
  • 10
    Cheuk DK, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011; 117: 197-206.
  • 11
    Mertens R, Granzen B, Lassay L, et al. Treatment of nasopharyngeal carcinoma in children and adolescents. Definitive results of a multicenter study (NPC-91-GPOH). Cancer. 2005; 104: 1083-1089.
  • 12
    Rodriguez-Galindo C, Wofford M, Castleberry RP, et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer. 2005; 103: 850-857.
  • 13
    Bakkal BH, Kaya B, Berberoglu S, et al. The efficiency of different chemoradiotherapy regimens in patients with paediatric nasopharynx cancer: review of 46 cases. Int J Clin Pract. 2007; 61: 52-61.
  • 14
    Cannon T, Zanation AM, Lai V, Weissler MC. Nasopharyngeal carcinoma in young patients: a systematic review of racial demographics. Laryngoscope. 2006; 116: 1021-1026.
  • 15
    Frikha M, Toumi N, Ghorbel L, et al. Pediatric nasopharyngeal carcinoma: anatomoclinic aspects, therapeutic results and evolutive particularities. Cancer Radiother. 2010; 14: 169-175.
  • 16
    Haimi M, Arush MW, Bar-Sela G, et al. Nasopharyngeal carcinoma in the pediatric age group: the Northern Israel (Rambam) Medical Center experience, 1989-2994. J Pediatr Hematol Oncol. 2005; 27: 510-516.
  • 17
    Hong J, Liao Y, Yuan J, Wei R, Wang X, Mao H. Clinical and prognostic analysis of nasopharyngeal carcinoma in 44 children and adolescents. Zhong Nan Da Xue Bao Yi Xue Ban. 2008; 33: 723-726.
  • 18
    Jmal A, Boussen H, Ghanem A, et al. Nasopharyngeal carcinoma in Tunesian children: retrospective epidemiological, clinical and biological study about 48 cases. Bull Cancer. 2005; 92: 977-981.
  • 19
    Laskar S, Bahl G, Muckaden M. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 72: 728-736.
  • 20
    Orbach D, Brisse H, Helfre S, et al. Radiation and chemotherapy combination for nasopharyngeal carcinoma in children: radiotherapy dose adaption after chemotherapy response to minimize late effects. Pediatr Blood Cancer. 2008; 50: 849-853.
  • 21
    Shen C, Gao Y, Xu T, Wang X, Ying H, Hu C. Carcinoma of the nasopharynx in young patients: a single institution experience. Clin Oncol (R Coll Radiol). 2009; 21: 617-622.
  • 22
    Taheri-Kadkhoda Z, Bjork-Eriksson T, Johannson KA, Mercke C. Long-term treatment results for nasopharyngeal carcinoma: the Sahlgrenska University Hospital experience. Acta Oncol. 2007; 46: 817-827.
  • 23
    Varan A, Ozyar E, Corapcioglu F, et al. Pediatric and young adult nasopharyngeal carcinoma patients treated with preradiation cisplatin and docetaxel chemotherapy. Int J Radiat Oncol Biol Phys. 2009; 73: 1116-1120.
  • 24
    American Joint Committee on Cancer. AJCC Cancer Staging Manual, past editions. Available from: Accessed January 5, 2011.
  • 25
    World Health Organization (WHO). WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 48. Geneva, Switzerland: World Health Organization; 1979.
  • 26
    Treuner J, Niethammer D, Dannecker G, Hagmann R, Neef V, Hofschneider PH. Successful treatment of nasopharyngeal carcinoma with interferon. Lancet. 1980; 1: 817-818.
  • 27
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 28
    Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons, Inc.; 1980.
  • 29
    SAS Institute, Inc. SAS [computer program]. Cary, NC: SAS Institute, Inc.; 2011.
  • 30
    R Foundation for Statistical Computing. R, version 2.12.1 [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2011.
  • 31
    National Cancer Institute. Stage Information for nasopharyngeal cancer. Available from: Accessed January 30, 2011.
  • 32
    Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008; 20: 264-269.
  • 33
    Chan WK, Mak HK, Huang B, Yeung DW, Kwong DL, Khong PL. Nasopharyngeal carcinoma: relationship between 18F-FDG Pet-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification. Nucl Med Commun. 2010; 31: 206-210.
  • 34
    Gordin A, Golz A, Daitzchman M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys. 2007; 68: 370-376.
  • 35
    Ng SH, Chan SC, Yen TC, et al. Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. Eur Radiol. 2010; 20: 2229-2240.
  • 36
    Xie P, Yue JB, Zhao HX, Kong L, Fu Z, Yu JM. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res. Clin Oncol. 2010; 136: 883-889.
  • 37
    Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence. Concept and preliminary results of the cooperative GPOH study NPC-91. Cancer. 1997; 80: 951-959.
  • 38
    Wolff HA, Rodel RM, Gunawan B, et al. Nasopharyngeal carcinoma in adults: treatment results after long-term follow-up with special reference to adjuvant interferon-beta in undifferentiated carcinomas. J Cancer Res Clin Oncol. 2010; 136: 89-97.
  • 39
    Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005; 23: 1118-1124.
  • 40
    Lee N, Harris J, Garden AS, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group phase II trial 0225. J Clin Oncol. 2009; 27: 3684-3690.
  • 41
    Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006; 65: 161-168.
  • 42
    Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 2005; 23: 8942-8949.
  • 43
    Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 2010; 33: 983-990.
  • 44
    Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005; 105: 1898-1904.
  • 45
    Yufeng D, Guocheng Z, Dongliang X, et al. Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro. Med Oncol. 2009; 26: 78-85.